Pulsed-Field Ablation (PFA)
Definition
Pulsed-field ablation (PFA) is a non-thermal catheter-based energy modality that uses high-voltage electrical pulses to achieve irreversible electroporation of cardiac cell membranes. Unlike radiofrequency or cryoablation, PFA is tissue-selective — cardiac myocytes are preferentially susceptible — and does not cause coagulative necrosis, conferring specific safety advantages for adjacent non-cardiac structures (oesophagus, phrenic nerve, pulmonary vein walls).
Key Concepts
Mechanism and Core Advantages
- Tissue selectivity: Cardiac myocytes are selectively susceptible to electroporation fields; adjacent oesophagus, phrenic nerve, and PV walls are spared (sources/ca-af-ehj-2024, rating: high)
- No coagulative necrosis: Eliminates risk of PV stenosis — a recognized complication of RF ablation (sources/ca-af-ehj-2024)
- Ultra-rapid application: Significantly shorter procedure time compared with RF point-by-point ablation (sources/ca-af-ehj-2024)
- Not contact-force dependent: Does not require the CF monitoring needed for RF ablation (sources/ca-af-ehj-2024)
Clinical Evidence
- ADVENT trial (PAF): PFA non-inferior to conventional thermal ablation (RF or cryoablation) for freedom from recurrence, AAD use, cardioversion or repeat ablation, and serious procedural adverse events (sources/ca-af-ehj-2024, rating: high)
- PULSED AF and PersAFOne: Confirmed safety and efficacy in both PAF and persistent AF; adjunctive LAPW ablation demonstrated feasible (sources/ca-af-ehj-2024)
- European real-world all-comer registry: Safe and effective for PVI and additional extra-PV lesions (mostly LAPW) in an unselected AF population (sources/ca-af-ehj-2024)
- MANIFEST-PF retrospective registry: Adjunctive LAPWI with PFA not beneficial at 12 months; criticised for small sample (131 patients/24 centres), unverified lesion durability, variable operator protocol, and inconsistent arrhythmia monitoring (sources/ca-af-ehj-2024)
Safety Profile
- No PV stenosis: Absence of coagulative necrosis eliminates this classic RF complication (sources/ca-af-ehj-2024)
- No oesophageal injury or phrenic nerve palsy: Core advantage; documented across multiple studies (sources/ca-af-ehj-2024)
- Coronary vasospasm: Risk when energy is delivered adjacent to coronary artery; effectively attenuated by prophylactic nitroglycerin administration (sources/ca-af-ehj-2024)
- Acute kidney injury (AKI): Secondary to intravascular haemolysis; dose-dependent on number of PFA applications; preventable by planned peri-procedural fluid infusion (sources/ca-af-ehj-2024)
- Pulmonary hypertension: PFA prevents worsening of pulmonary hypertension (unlike RF) in AF patients with baseline stiff left atrial syndrome (sources/ca-af-ehj-2024)
- Thromboembolic events: TIA 0.8% (IMPULSE/PEFCAT I/II); stroke 0.39%, TIA 0.11% (MANIFEST-PF); MRI-detected cerebral lesions mostly transient — 97% normal MRI at 40-day follow-up in one series (sources/ca-af-ehj-2024)
Gaps and Future Directions
- Longer-term safety data are still absent (sources/ca-af-ehj-2024)
- Optimal role of adjunctive ablation beyond PVI in persistent AF with PFA requires dedicated RCTs (sources/ca-af-ehj-2024)
- Applicability in all-comer AF populations and full characterisation of rare side effects (AKI, coronary vasospasm) require large-scale trials (sources/ca-af-ehj-2024)
Ventricular PFA (Emerging)
- PFA has been used for ventricular arrhythmias (PVCs and VT) but experience remains limited; no large published series (sources/PVC-ablation-jaccep-2024, rating: high)
- Tissue selectivity (cardiomyocyte-specific) and minimal heat generation are theoretically advantageous for ventricular use: reduced risk of steam pops, char formation, and thromboembolism compared with RF (sources/PVC-ablation-jaccep-2024)
- No specific ventricular PFA outcome data available at time of 2024 review; characterised as "emerging" (sources/PVC-ablation-jaccep-2024)
Contradictions / Open Questions
- MANIFEST-PF found no benefit of adjunctive LAPWI with PFA at 12 months, in contrast to RF/cryo-based meta-analyses showing benefit; methodological limitations of MANIFEST-PF make the negative result uncertain (sources/ca-af-ehj-2024)
- Optimal lesion set beyond PVI in persistent AF with PFA is unresolved; no dedicated RCT yet completed (sources/ca-af-ehj-2024)
- Long-term durability of PFA lesions (vs RF or cryo) not yet established in large prospective studies
Connections
- Related to concepts/Catheter-Ablation-AF
- Related to entities/Atrial-Fibrillation
- Related to sources/ca-af-ehj-2024